---
title: "CD38–NAMPT–p21 signaling drives stress resilience in CLL cells"
id: "biorxiv-4-cd38-nampt-p21-signaling-promotes-stress-adaptation-in-cll"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-4-cd38-nampt-p21-signaling-promotes-stress-adaptation-in-cll"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1?rss=1"
published_at: "2026-11-18T09:20:07.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# CD38–NAMPT–p21 signaling drives stress resilience in CLL cells
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-4-cd38-nampt-p21-signaling-promotes-stress-adaptation-in-cll
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1?rss=1)
- **Published At:** 2026-11-18T09:20:07.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators reported that **CD38** functions beyond a prognostic surface marker in chronic lymphocytic leukemia (**CLL**) and acts as a metabolic and signaling regulator that helps cells resist stress. - The study team engineered MEC-1 cells to express CD38 and contrasted them with cells carrying a catalytically inactive CD38 mutant; the active enzyme generated a distinct survival phenotype under cytotoxic and hypoxic conditions. - Data indicated that **CD38** NADase activity promoted upregulation of **NAMPT**, activation of AKT signaling, and accumulation of cytoplasmic **p21**, forming a CD38–NAMPT–p21 survival axis linked to resistance to fludarabine and hypoxia. - The CD38-dependent survival program was reversed by pharmacologic inhibition of NAMPT (FK866) and by suppression of p21 (UC2288), according to the authors. - Single-cell RNA-sequencing datasets from primary CLL samples showed that naturally occurring CD38-positive cells expressed higher **NAMPT** and related stress-response genes, matching engineered-cell findings. - Larger primary cohort analyses associated **NAMPT** expression with AKT and hypoxia gene signatures in patient-derived CLL, supporting clinical relevance of the pathway. - The report is a preprint and has not been peer-reviewed; the authors suggested that targeting **NAD⁺** metabolism and **p21**-mediated survival could be explored as strategies for CD38-high disease, but detailed therapeutic dosing, clinical endpoints, or in vivo validation were not reported in the source. - Authors declared no competing interests. Funding included an NIH Common Fund grant (R01CA233790-3).
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=OyxHysdL_uU1_T0QBaW51gg6s82gVo1IEEgUyCB.Rx4-1794993639.834543-1.2.1.1-un.N8kYTNAsWd1TI50LNeRtMK9Ct9t6rW8CUYoRmttxQp3JoUwBhbCwrIL7AeSs4) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # CD38-NAMPT-p21 signaling promotes stress adaptation in CLL [ View ORCID Profile](http://orcid.org/0000-0002-0818-409X)BING HAN, Claudia CS Chini, GINA CICCIO LOPEZ, YUKI HAMADA, ANEEL PAULUS, ASHER CHANAN-KHAN, ESTEBAN BRAGGIO, ANDERS BERGLUND, Eduardo Nunes Chini doi: https://doi.org/10.64898/2026.11.16.766865 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. BING HAN 1 MAYO CLINIC; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=BING%2BHAN%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=HAN%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ABING%2BHAN%2B) * [ORCID record for BING HAN](http://orcid.org/0000-0002-0818-409X "Open in new tab") Claudia CS Chini 2 Mayo Clinic * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Claudia%2BCS%2BChini%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Chini%20CC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AClaudia%2BCS%2BChini%2B) GINA CICCIO LOPEZ 1 MAYO CLINIC; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=GINA%2BCICCIO%2BLOPEZ%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=CICCIO%20LOPEZ%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AGINA%2BCICCIO%2BLOPEZ%2B) YUKI HAMADA 1 MAYO CLINIC; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=YUKI%2BHAMADA%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=HAMADA%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AYUKI%2BHAMADA%2B) ANEEL PAULUS 1 MAYO CLINIC; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=ANEEL%2BPAULUS%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=PAULUS%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AANEEL%2BPAULUS%2B) ASHER CHANAN-KHAN 1 MAYO CLINIC; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=ASHER%2BCHANAN-KHAN%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=CHANAN-KHAN%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AASHER%2BCHANAN-KHAN%2B) ESTEBAN BRAGGIO 1 MAYO CLINIC; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=ESTEBAN%2BBRAGGIO%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=BRAGGIO%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AESTEBAN%2BBRAGGIO%2B) ANDERS BERGLUND 1 MAYO CLINIC; * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=ANDERS%2BBERGLUND%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=BERGLUND%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AANDERS%2BBERGLUND%2B) Eduardo Nunes Chini 2 Mayo Clinic * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Eduardo%2BNunes%2BChini%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Chini%20EN&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AEduardo%2BNunes%2BChini%2B) * For correspondence: chini.eduardo@mayo.edu * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5972328/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5972328/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5972328/1) * [Supplementary material](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1.supplementary-material)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_data/node:5972328/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5972328/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States, accounting for ~30% of new diagnoses and ~4,000 deaths annually. High CD38 expression is a well-established marker of poor prognosis, yet the mechanistic basis of CD38-mediated treatment failure has remained incompletely understood. Here, we demonstrate that CD38 functions not merely as a prognostic biomarker but as a metabolic and signaling regulator that equips CLL cells to withstand cytotoxic and hypoxic stress. Using MEC-1 cells engineered to express CD38, we identified a CD38-NAMPT-p21 survival axis that confers resistance to fludarabine and hypoxia. CD38 NADase activity promoted NAMPT upregulation and AKT activation and was associated with accumulation of cytoplasmic p21. This CD38-dependent phenotype was lost in cells expressing a catalytically inactive CD38 mutant and was also reversed by pharmacologic inhibition of NAMPT (FK866) or suppression of p21 (UC2288). Analysis of three independent single-cell RNA-sequencing datasets of primary CLL further showed that naturally occurring CD38-positive CLL cells exhibit increased NAMPT expression and related stress-response signaling. Analysis of larger primary CLL cohorts further linked NAMPT expression to AKT and hypoxia signatures, providing additional support for the relevance of this pathway in patient-derived CLL. Together, these findings identify CD38-NAMPT-p21 signaling as an important mechanism of stress adaptation in CLL and suggest that targeting NAD⁺ metabolism and p21-mediated survival pathways may represent a potential strategy for CD38-high disease. ### Competing Interest Statement The authors have declared no competing interest. ## Funder Information Declared NIH Common Fund, https://ror.org/001d55x84, R01CA233790-3 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.11.16.766915v1 "Development of synthetic genetic arrays for studying interactions between the mitochondrial and nuclear genomes")[Next ](https://www.biorxiv.org/content/10.64898/2026.11.16.767153v1 "Rank Deficiency in Parameter Estimation for Hodgkin-Huxley Type Current Models") Posted November 18, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/18/2026.11.16.766865.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [Supplementary Material ](https://www.biorxiv.org/content/10.64898/2026.11.16.766865v1.supplementary-material) [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) CD38-NAMPT-p21 signaling promotes stress adaptation in CLL BING HAN, Claudia CS Chini, GINA CICCIO LOPEZ, YUKI HAMADA, ANEEL PAULUS, ASHER CHANAN-KHAN, ESTEBAN BRAGGIO, ANDERS BERGLUND, Eduardo Nunes Chini bioRxiv 2026.11.16.766865; doi: https://doi.org/10.64898/2026.11.16.766865 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.16.766865v1%26text%3DCD38-NAMPT-p21%2520signaling%2520promotes%2520stress%2520adaptation%2520in%2520CLL "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.16.766865v1%26t%3DCD38-NAMPT-p21%2520signaling%2520promotes%2520stress%2520adaptation%2520in%2520CLL "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.16.766865v1%26title%3DCD38-NAMPT-p21%2520signaling%2520promotes%2520stress%2520adaptation%2520in%2520CLL%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.16.766865v1%26title%3DCD38-NAMPT-p21%2520signaling%2520promotes%2520stress%2520adaptation%2520in%2520CLL "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation
## Related Clinical Research

- [SLC6A8 creatine transporter identified as an immune pressure–exposed metabolic vulnerability in ac](https://medichelpline.com/clinical-feed/biorxiv-0-the-creatine-transporter-slc6a8-is-an-immune-pressure-exposed-metabolic.md)
- [High-fat Diets Reprogram Intestinal Stem Cells and May Raise Colon Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fat-diets-leave-memory-in-gut-stem-cells-that-may-fuel-colon-cancer.md)
- [Camupepimut KRAS Vaccine Induces Strong Immune Responses in Phase 2 Pancreatic Cancer Trial](https://medichelpline.com/clinical-feed/medical-news-today-0-experimental-pancreatic-cancer-vaccine-shows-promise-in-clinical-trial.md)
- [Promoter Architecture Drives Selective **Menin-KMT2A** Occupancy at Developmental and Leukemia Gen](https://medichelpline.com/clinical-feed/biorxiv-4-a-unique-promoter-architecture-defines-menin-kmt2a-complex-selectivity.md)
- [Psychotropic drug prescribing trends in Dutch nursing home residents with dementia, 2016–2023](https://medichelpline.com/clinical-feed/plos-one-17-trends-in-psychotropic-drug-use-in-nursing-home-residents-with-dementia-and.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.